Contemporary role of avelumab first-line maintenance in advanced urothelial carcinoma with consideration of the JAVELIN Bladder 100 comprehensive clinical subgroup analyses

Transl Androl Urol. 2024 Mar 31;13(3):463-466. doi: 10.21037/tau-23-576. Epub 2024 Mar 18.

Authors

Kevin K Zarrabi¹, Benjamin Miron², Daniel M Geynisman²

Affiliations

¹ Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
² Department of Medical Oncology, Fox Chase Cancer Center, Temple University Hospital, Philadelphia, PA, USA.

No abstract available

Keywords: Urothelial carcinoma (UC); enfortumab vedotin (EV); immunotherapy.

Publication types

Editorial
Comment